Acumen Pharmaceuticals (ABOS) Citigroup’s Biopharma Back to School Summit 2026 summary

Market and pipeline overview

• Alzheimer's market is expanding rapidly, with two approved agents expected to reach $3–4 billion in annual sales by 2030, highlighting significant unmet need and commercial opportunity.

• Current pipeline includes sabirnetug, a phase II asset targeting toxic A-beta oligomers, with data expected later this year, and a preclinical EBD program aiming for IND in 2027.

• Amyloid targeting is now validated as a disease-modifying strategy, with sabirnetug designed for high selectivity against oligomers, potentially offering improved efficacy and safety.

• The EBD program leverages transferrin-mediated transport to enhance brain delivery of antibodies, with two candidates advancing toward IND.

Scientific rationale and trial design

• Oligomers are identified as the most toxic amyloid species, disrupting synaptic function early in Alzheimer's progression.

• Sabirnetug selectively targets oligomers, with phase I data showing robust target engagement and biomarker movement.

• ALTITUDE-AD is a double-blind, placebo-controlled phase II study with 542 patients, testing two doses over 18 months, followed by a 12-month open-label extension.

• Primary endpoint is iADRS, combining cognitive and functional measures, with extensive biomarker analysis included.

Differentiation, efficacy, and safety

• Targeting oligomers may yield greater efficacy and earlier cognitive benefit compared to existing therapies, aiming for at least 30% slowing in cognitive decline.

• Phase I ARIA rate was about 10%, mostly non-symptomatic, with higher rates at doses not advanced to phase II.

• ALTITUDE-AD's patient selection and entry criteria closely mirror lecanemab trials, focusing on early Alzheimer's (MCI and mild dementia) without tau requirements.

• Efficient plasma-based pre-screening improved trial enrollment and patient targeting.